David S. Boyer, MD, provides an overview of the phase 2 DEL MAR study with ALG-1001 (Luminate, Allegro) in patients with diabetic macular edema. With stage 1 of the study previously presented, Dr. Boyer details the recent findings of stage 2, which evaluated the safety and efficacy of ALG-1001 with bevacizumab (Avastin, Genentech) pretreatment or ALG-1001 combined with bevacizumab.
To view the video, please visit Eyetube: “DEL MAR: Phase 2, Stage 2”
